Immuron share price shoots 90% higher on potential COVID-19 treatment news

The Immuron Limited (ASX: IMC) share price has shot 90% higher today following a release regarding the effect of its flagship drug Travelan on Covid-19.

| More on:
Chalk-drawn rocket shown blasting off into space

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immuron Limited (ASX: IMC) share price is up by 89.80% to 46 cents per share this morning on news that Immuron's product IMM-124E has neutralising activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.

This follows on from another positive announcement yesterday that the U.S. Food and Drug Administration (FDA) provided guidance about the development pathway for Immuron's new oral therapeutic drugs.

What sent Immuron's share price skyrocketing?

The Immuron share price has shot higher in early trade following news that IMM-124E, which is used in the manufacture of Immuron's flagship drugs Travelan and Protectyn, demonstrates antiviral activity against COVID-19 in laboratory testing.

Trevelan is Immuron's only drug that currently generates revenue and is predominantly used to reduce the risk of traveller's diarrhoea and minor gastro-intestinal disorders. It is licensed in Australia, Canada and sold as a dietary supplement in the US.

The company reports that the cytopathic effect inhibition cell-based assay was established and performed by 360 biolabs, a Melbourne-based contract research organisation. All 4 of the tests performed saw inhibition of Covid-19 of at least 50%. Higher concentrations of IMM-124E stemmed the virus replication by up to 90%. None of the tests demonstrated any cell toxicity.

Commenting on the early results, Immuron CEO Dr Jerry Kanellos stated: 

The preliminary data set we have generated potentially offers a new oral therapeutic approach to target and directly inhibit the virus in the Gastrointestinal tract and warrants further evaluation to identify the inhibitory substances in our products. The company has filed a provisional patent application in respect of the findings.

What now for Immuron?

Immuron is an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens such as campylobacteriosis and E. coli (ETEC).

After languishing around the 12 cent mark over the past year, the Immuron share price has seen a stark reversal in fortunes, jumping 275% on 9 June alone, in response to news of briefing documentation being submitted to the FDA. The Immuron share price is up 253% year to date, and currently sits at 46 cents per share.

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a cracking end to the trading week for ASX investors.

Read more »

Two brokers analysing stocks.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman and man calculating a dividend yield.
Opinions

Buy or bail? Fundie's verdict on 2 ASX 300 shares

Stuart Bromley of Medallion Financial Group provides his insights.

Read more »

A man analyses stockmarket graph on his computer.
Share Market News

US stocks vs. ASX shares in FY25

Would you be surprised to learn that ASX tech shares rose faster than US tech stocks by almost 2:1?

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Gainers

Why ARB, Cleanaway, Hub24, and RPMGlobal shares are storming higher today

These shares are ending the week with a bang. But why?

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Evolution Mining, G8 Education, Lottery Corp, and Lynas shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in July

These stocks could be best buys this month according to the broker.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Macquarie tips 55% upside for this ASX mining stock

Let's see what the broker is saying about this stock.

Read more »